Jean-Pierre Sommadossi sold $234k of AVIR
President, CEO, and Chairman at Atea Pharmaceuticals, Inc.. 57,969 shares at an average of $4.04, traded Sep 17, 2024, filed Sep 19, 2024.
Score components
- +25RoleCEO
- +13Trade size$234k at market
- 0Share of holdings soldSold 1.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-108233, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | SOpen-market sale Common Stockindirect: Held by JPM Partners LLC10b5-1 | -33,941 | $4.05 | $137k | 5,890,053 | Sep 19, 2024 |
| Sep 18, 2024 | SOpen-market sale Common Stockindirect: Held by JPM Partners LLC10b5-1 | -22,187 | $4.03 | $89k | 5,867,866 | Sep 19, 2024 |
| Sep 19, 2024 | SOpen-market sale Common Stockindirect: Held by JPM Partners LLC10b5-1 | -1,841 | $4.00 | $7,368 | 5,866,025 | Sep 19, 2024 |
Related signals
Other insiders at Atea Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | AVIRbuy Atea Pharmaceuticals, Inc. | Polly A. Murphy director | $25k 6,100 shares | +7% | |
| 41Moderate | AVIRbuy Atea Pharmaceuticals, Inc. | Polly A. Murphy director | $25k 6,100 shares | +7% | |
| 27Weak | AVIRbuy Atea Pharmaceuticals, Inc. | Franklin M Berger director | $81k 25,000 shares | +6% | |
| 50Moderate | AVIRsell Atea Pharmaceuticals, Inc. | Franklin M Berger director | $1.0M 359,606 shares | -44% | |
| 27Weak | AVIRsell Atea Pharmaceuticals, Inc. | Bruce Polsky director | $61k 17,544 shares | -21% | |
| 5Weak | Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi President, CEO, and Chairman | $4,024 1,006 shares | -0% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Janet MJ Hammond Chief Development Officer | $54k 14,029 shares | -28% | |
| 11Weak | Atea Pharmaceuticals, Inc. | John Vavricka Chief Commercial Officer | $45k 11,819 shares | -35% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Wayne Foster EVP, Chief Accounting Officer | $48k 12,477 shares | -37% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Maria Arantxa Horga Chief Medical Officer | $61k 15,870 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.